New Blood Test Detects Advanced Alzheimer’s Tau Tangles With 50.5-Fold Increase Over Early Stages
An Alzheimer’s blood test was expected to measure only soluble tau proteins — what happened instead is that a new assay published online in JAMA on November 16 detected late-stage, insoluble tau tangles at levels up to 50.5-fold higher in advanced disease, Medscape reported.
- A new high-sensitivity blood test for eMTBR-tau, a marker of insoluble tau tangles, tracked advanced Alzheimer’s pathology far more steeply than the existing p-tau217 blood marker.
- The test needs just 35 microliters of plasma and matched a far more complex mass spectrometry method in accuracy.
- Researchers caution the findings are cross-sectional and early; the test is not yet validated for clinical use.
It evaluated plasma eMTBR-tau243 — endogenously cleaved microtubule-binding region tau — in 521 brain donors from two US autopsy cohorts with blood samples collected before death, plus 207 participants from two tau PET imaging cohorts, according to the JAMA paper.
Why the result matters: plasma phosphorylated tau 217 (p-tau217) is increasingly used to identify amyloid pathology, but it is less specific for the insoluble tau tangles that more closely track neurodegeneration and cognitive decline. Plasma eMTBR-tau243 has emerged as a promising marker of those tangles, yet testing until now has relied on mass spectrometry, available in relatively few laboratories.
Two Markers, Two Very Different Curves
The contrast with p-tau217 was stark at the most advanced stage:
| Biomarker | Cohort 1 (stage VI vs I-II) | Cohort 2 (stage VI vs I-II) |
|---|---|---|
| eMTBR-tau | 50.5-fold higher | 25.2-fold higher |
| p-tau217 | 4.6-fold higher | 3.2-fold higher |
Both comparisons were statistically significant (P < .001 for both), per the JAMA study. The gap illustrates the pathophysiologic distinction the researchers are drawing on: soluble tau versus the insoluble tangles that define late-stage disease.
In one autopsy cohort, eMTBR-tau also outperformed p-tau217 in distinguishing advanced from earlier Braak stages, with an area under the curve (AUC) of 0.93 versus 0.84 (P < .001). The difference was not statistically significant after adjustment in the second cohort.
Imaging Cohorts Back the Autopsy Data
Findings from the tau-PET imaging cohorts reinforced the neuropathologic results.
In the BioFINDER-2 cohort, the immunoassay showed strong agreement with mass spectrometry, with a correlation coefficient of 0.93 overall and 0.96 among amyloid-positive participants. Both methods identified regional tau-PET positivity with similarly high accuracy — AUCs of 0.96 to 0.99 for the immunoassay and 0.97 to 0.99 for mass spectrometry.
Where the Test Falls Short
The investigators acknowledged several limitations in the JAMA paper: the cross-sectional design, relatively small imaging cohorts, and limited racial and ethnic diversity. Many eMTBR-tau values at early Braak stages fell below the assay’s lower limit of quantification.
For now, the immunoassay may be most useful for expanding research into blood-based staging of Alzheimer’s disease, potentially complementing existing biomarkers such as p-tau217, the investigators noted.
A Panel Rather Than a Replacement
More data are needed, she said, to determine how the findings translate into clinical practice and whether they could help identify patients most likely to benefit from treatment.
Funding and Conflicts on the Record
The study was supported by multiple research grants and foundations, according to the JAMA paper. Bioventix supplied antibodies, and Alamar Biosciences performed the immunoassay measurements. Ashton reported advisory, educational, and consulting relationships with multiple companies, including Alamar Biosciences. Marcal reported no disclosures.
What This Means for Patients Now
No clinical cutoffs exist yet, and the test remains a research tool — patients should not expect it in routine screening until prospective validation is complete.
Published by the American Medical Association since 1883, JAMA is described by its publisher as the most widely circulated general medical journal in the world, with more than 101,000 print recipients and over 29 million annual website visits. It accepts roughly 10% of more than 11,500 annual submissions, and in 2016 it published the first academic paper ever written by a sitting US president, Barack Obama.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.
- GATA6 Modulates Metabolism to Influence Chemotherapy Sensitivity in NSCLC
- Tunisia’s Institute to Host Training on Glycemic Variability
- November 20: World Children’s Day, Nuremberg Trials, Windows 1.0, Artificial Blood (archyde.com)
- Researchers Develop Blood Test to Track Alzheimer’s Progression (time.news)